Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy.

Institut Gustave Roussy, Villejuif, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Villejuif
Treatments:ChemotherapyHospital:Institut Gustave Roussy
Drugs:Journal:Link
Date:Apr 2003

Description:

Patients: This multicentre Phase II study involved 52 patients with glioblastoma multiforme who had not been administered chemotherapy previously. Patients were divided into two groups – 25 patients in group A and 27 patients in group B. Group A consisted of patients with the following characteristics: 1) newly diagnosed glioblastoma; 2) tumor inoperable or incompletely resected; 3) no radiotherapy administered. Group B consisted of patients whose tumor was relapsing after they had already received radiotherapy.

Treatment: Treatment consisted of the chemotherapy drug, irinotecan (camptosar). (In addition, patients in group A would also receive radiotherapy if appropriate.)

Toxicity: Toxicities included grade 3-4 cholinergic syndrome with acute diarrhea, abdominal pain, nausea, vomiting, hypersalivation, sweating and asthenia. Grade 3-4 neutropenia was reported in a total of ten patients (3 in group A and 7 in group B). One patient (in group A) had grade 3 anemia.

Results: The median overall survival was 5.8 months in group A.

Support: Aventis Pharma supplied the irinotecan.

Correspondence: Dr. Eric Raymond





Back